Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Abstract Background We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF. Methods We identify all approved indications of immune checkpoint inhibitors based on RCTs between January...

Full description

Bibliographic Details
Main Authors: Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Cancer
Subjects:
Randomized trials
Clinical benefits
Immune checkpoint inhibitors
Cancer
Food and drug administration agency
Online Access:http://link.springer.com/article/10.1186/s12885-020-07313-2

Internet

http://link.springer.com/article/10.1186/s12885-020-07313-2

Similar Items